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Abstract
Objectives: Patients with overactive bladder (OAB) often have trouble perceiving urgency because of difficulties in
distinguishing between urgency and desire to void. Empirical antimuscarinic treatment of patients with frequency only may
be reasonable if conservative management has failed. We compared the efficacy of solifenacin in patients with frequency
with or without urgency.
Materials and Methods: This multicenter, 12-week, open-label, comparative, non-inferiority clinical trial assessed whether
the solifenacin efficacy for frequency without urgency is non-inferior to its efficacy for frequency with urgency. All patients
had micturition frequency $8 voids/day with or without urgency. Primary efficacy variable: daily frequency change at 12
weeks relative to baseline. Secondary efficacy variables: change at 12 weeks relative to baseline in Patients’ Perception of
Bladder Condition (PPBC), OAB Symptom Score (OABSS), and Benefit, Satisfaction, Willingness to continue (BSW)
questionnaire.
Results: Of the 286 enrolled patients, 240 (83.9%) completed the study (without urgency n= 115; with urgency n = 125). Full
dataset analysis revealed that the groups without and with urgency exhibited significant reductions in daily micturition
frequency of 22.4960.35 (mean6 standard error) and22.6360.37, respectively. The lower limit of the 95% two-sided CI of
the comparison of the two group means was 21.14, which is smaller than the 20.8 margin of clinical equivalence. The two
groups did not differ in improvement in PPBC, OABSS, or BSW scores. Both tolerated the treatment well.
Conclusions: It was not possible to verify that the solifenacin efficacy for frequency alone was non-inferior to its efficacy for
OAB. Nevertheless, solifenacin tended to be effective for frequency regardless of urgency.
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Introduction
Overactive bladder (OAB) is defined by the International
Continence Society (ICS) as urgency [with or without urgency
urinary incontinence (UUI)] that is usually associated with
frequency and nocturia [1]. This definition suggests that urgency
is the key symptom for a diagnosis of OAB, and as such, OAB
cannot be diagnosed in the absence of urgency and is thought to
be a driver for all other symptoms of OAB including frequency,
nocturia, and UUI [2]. Due to its primary role in defining the
OAB syndrome, it is important for clinicians to have a reasonable
understanding of the definition of urgency.
The ICS defines urgency as ‘‘the complaint of a sudden
compelling desire to pass urine which is difficult to defer’’ [1]. This
assumes that urgency is an abnormal or pathological bladder
sensation that is distinguishable from the normal physiological
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sensation of urge to void [2,3]. In most studies of OAB, diagnosis
was based on physician identification of urgency according to the
ICS definition, and urgency was the primary endpoint. However,
greater clarity has been needed in the development of instruments
for measuring urgency, because it is generally difficult for patient
with OAB to perceive urgency and to differentiate urgency from
urge to void [4].
In clinical experience, it seems that many patients who present
with urinary frequency complain of a desire to void without
urgency as defined by ICS, yet it is not suited for the current ICS
definition of OAB. Nevertheless, despite the fact that urgency is
the key symptom in OAB, frequency is also regarded as one of the
most bothersome OAB symptom [5]. Despite this, the pathophys-
iology of frequency only and treatment guidelines for the
management of patients with frequency only have not been
established.
We hypothesized that the some of the patients who complained
of only frequency without urgency may be actually OAB patient
who cannot perceive or express their urgency symptoms, and
antimuscarinic drugs may be effective in patients who complained
of only urinary frequency without urgency, as they are in patients
with urgency. Thus, we compared the efficacy of solifenacin in
patients with frequency only and frequency with urgency.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1, Protocol
S1 and Protocol S2.
2.1. Study design
This multicenter, 12-week, open-label, comparative, non-
inferiority study was based on the hypothesis, ‘‘The efficacy of
solifenacin for frequency only is non-inferior to the efficacy of
solifenacin for frequency with urgency’’. It was conducted at nine
sites between April 2009 and September 2011 in Korea. The study
was conducted in accordance with the ethical principles in Korean
Good Clinical Practice, the Declaration of Helsinki, and the
International Conference of Harmonization Guidelines. This
study was approved by the Institutional Review Board of Asan
Medical Center (No. 2009-0014). Before enrollment in the study,
all patients provided written informed consent.
2.2. Study patients
The study population consisted of men and women aged $18
years with symptoms of frequency for more than 3 months. All
patients were assessed by a 3-day voiding diary and the urinary
sensation scale (USS) [6]. The voiding diary and USS were
carefully instructed by a study nurse who had been trained and
explained the meaning of urgency and USS to all patients.
Recording in voiding diary included day and night frequency,
voided volume, and USS for each void. In the USS, the grade of
urinary sensation perception was defined by scores from 1 to 5 as
follows: 1 = no urgency: no feeling of urgency (can continue
activities until it is convenient to use bathroom); 2 = mild urgency:
feel urgency (can easily tolerate; can finish usual activity and tasks
quickly, and then go straight to the bathroom); 3 = moderate
urgency: enough urgency discomfort (need to stop usual activity
and tasks, and go straight to the bathroom); 4 = severe urgency:
strong urgency discomfort (almost cannot hold urine; need to stop
usual activity and tasks immediately, and run to bathroom to avoid
a micturition accident); and 5= urge incontinence: extreme
urgency discomfort (cannot hold urine, and has a micturition
accident before reaching the bathroom). The mean score of USS
recorded on the 3-day voiding diary was considered as the USS for
the patient, and urgency was defined as USS $3 based on a
voiding diary.
The Patients were excluded if they had: significant stress urinary
incontinence, an average total daily urine volume .3000 ml,
serum liver enzymes or creatinine level.2 times the upper limit of
normal, symptomatic urinary tract infection at screening, recur-
rent urinary tract infections (defined as receiving treatment for
symptomatic urinary tract infections .4 times in the last year),
interstitial cystitis, urothelial tumor, a post-void residual (PVR)
urine volume .100 ml, clinically relevant bladder outlet obstruc-
tion, clinically significant pelvic organ prolapse, electrostimulation
treatment, undergone bladder training in the preceding 2 weeks,
received antimuscarinic medication in the preceding 2 weeks,
and/or neurological conditions that can specifically affect bladder
function.
2.3. Interventions
We classified the patients with average micturition frequency $
8/24 hours without urgency as Group 1, and patients with average
micturition frequency$8/24 hours with urgency (USS$3/3 days)
as Group 2, based on a 3-day voiding diary. Patients received
solifenacin 5 mg once daily. At the week 4 visit, the dose could be
increased to 10 mg based on discussion between the subject and
investigator regarding treatment efficacy and tolerability.
2.4. Efficacy and safety assessments
To assess efficacy, the patients completed a 3-day voiding diary
before the clinic visits at baseline and at weeks 4 and 12 (final visit).
The primary efficacy variable was change in daily micturition
frequency at 12 weeks relative to baseline. The secondary efficacy
variables were change from baseline in Patients’ Perception of
Bladder Condition (PPBC) [7], OAB Symptom Score (OABSS)
[8], and Benefit, Satisfaction, and Willingness to continue (BSW)
scores, as determined by questionnaires completed at baseline and
the end of treatment. Safety was evaluated by recording adverse
events and measuring maximal urinary flow rate (MFR) and PVR.
2.5. Statistical analyses
Sample size was calculated by using the Power Analysis and
Sample Size (PASS) statistical software package (PASS 11, NCSS,
LLC, Kaysville, UT, USA). Sample sizes of 128 evaluable patients
per treatment group were deemed to provide approximately 80%
power to detect a non-inferiority margin of equivalence of 20.8
(standard deviation: 2.56 [9]) in terms of change in mean
micturitions per 24 hours when Group 1 was compared to Group
2. Thus, 256 subjects were required. Based on an estimated 10%
dropout rate, it was planned to recruit 286 subjects.
To analyze the efficacy data, the full analysis set (FAS) was used,
namely, all patients who took the study medication and completed
at least one efficacy evaluation. Per protocol (PP) analysis was
performed for evaluation of changes in MFR and PVR relative to
baseline. Categorical data were compared with chi-square statistics
or Fisher’s exact test and presented as frequencies. Continuous
variables were analyzed using unpaired Student t- test and
presented as mean 6 standard error. All statistical tests had a two-
sided significance level of 0.05 and were performed by using SPSS
statistical software package (SPSS 21.0, SPSS, Chicago, IL).
Results
3.1. Baseline demographic data
A total of 286 patients were enrolled and 240 (83.9%)
successfully completed the 12-week treatment period (Group 1:
Efficacy of Solifenacin for Frequency
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115; Group 2: 125) (Figure 1). Twenty-six (18.4%) in Group 1 and
20 (13.8%) Group 2 patients dropped out. The two groups were
similar in terms of baseline demographic and clinical character-
istics (Table 1). Compliance for solifenacin at 12 weeks was 97.5%
and there was no significantly difference between the two groups
(97.0% vs. 98.0%, p=0.408).
3.2. Treatment efficacy
At 12 weeks, Groups 1 and 2 both exhibited statistically
significant reductions in average daily micturition frequency
relative to baseline (22.4960.35 and 22.6360.37; all p,0.001);
Table 2). There was no significantly difference between two
groups. However, the lower limit of the 95% two-sided CI of the
comparison of the two group means was 21.14, which is smaller
than the 20.8 margin of clinical equivalence (non-inferior p-value
= 0.099). Therefore, it cannot be said that the efficacy of
solifenacin for frequency alone was non-inferior to the efficacy
of solifenacin for frequency with urgency.
The two groups did not differ significantly in improvement in
OABSS, PPBC, or BSW scores (Table 3).
After 4 weeks of treatment, nine patients (7.8%) in Group 1 and
four (3.2%) in Group 2 requested a dose escalation to 10 mg. This
difference was not statistically significant. In Group 1, the
solifenacin escalators had significantly more micturition episodes
at baseline than the non-escalators (12.1061.07 vs. 14.8161.56,
p=0.019). The solifenacin escalators and non-escalators in Group
2 did not differ significant in terms of this variable.
3.3. Safety
Adverse events were reported in 25.5% (36/141) in Group 1
and 39.3% (57/145), and the difference was not significant.
However, these adverse events were generally mild (Table 4). Dry
mouth was the most frequently reported adverse reaction. The two
groups did not differ significantly in terms of MFR and PVR
changes relative to baseline (21.461.05 vs.20.1160.92 ml/s and
5.562.99 vs. 9.363.94 ml, respectively).
Discussion
To the best of our knowledge, this is the first trial to evaluate the
efficacy of an antimuscarinic agent for frequency without urgency.
We demonstrated a reduction of approximately two frequency
episodes per day in patients with frequency without urgency at
week 12, which was similar to that in patients with frequency with
urgency, as well as the mean change in daily micturition of
antimuscarinic treatment in meta-analysis [10]. The PPBC and
BSW questionnaires revealed that the treatment had positive
effects in the patients with frequency without urgency, which
indicates that the treatment induced clinical meaningful improve-
ments in micturition frequency in this group.
Urinary urgency is the cornerstone of the definition of OAB that
is estimated to affect 10% of the worldwide population [11],
however yet we know little about the definite cause, effect on
voiding behavior, or proper measurement of urgency. OAB
patients might modify voiding behavior to avoid showing urgency
Figure 1. Participant flowchart.
doi:10.1371/journal.pone.0112063.g001
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or urgency incontinence. Therefore, their episodes of urgency may
be underestimated or hidden behind frequency only. This can lead
to confusion in diagnosis and treatment decision of OAB.
At present, the pathophysiology of frequency without urgency is
poorly understood. The most common cause of frequency only
would be that the vast majority of patients do not understand the
subtle diagnostic nuances of urinary urgency. Indeed, a study on
patient understanding of lower urinary tract symptoms showed
that the term ‘‘urgency’’ was correctly defined by only 46% of the
subjects [12]. A study examining how patients described their urge
or desire to urinate reported diverse descriptions, including
frequency, full bladder, relief, necessity, and must go [13].
Although the USS has good content validity, discriminated
validity, and test-retest reliability [14], it may not capture the
patient’s experience of urinary urgency thoroughly as other
current urgency scales [15]. It may be that these patients void
frequently with no preceding desire to void to avoid more
compelling situations; this is known as convenience voiding [16].
Healthy volunteers may empty their bladders early for social
reasons, such as before joining a meeting, going out on a long
journey, or retiring to bed at night [17]. Specifically, OAB patients
go to the toilet more often to avoid urgency or leakage because
they know of their sudden urgency or urgency incontinence. In
these patients, once this decision to convenience void is made,
most voiding may be initiated with mild sensations rather than
sensation of immediate needing to void. The third explanation of
frequency only is the lack of the progressive increase in bladder
awareness [18]. These subjects report frequent voiding, which
appears to originate from their cognitive strategies to avoid intense
urge sensation and incontinence. Thus, interpreting bladder
awareness may be depressed in pathological states. Further study
is necessary to confirm this modified view for determining the
decision to void.
The clinically significant efficacy of an antimuscarinic agent in
our patients with frequency without urgency may be explained by
an inhibitory effect of this agent on afferent bladder nerves.
Antimuscarinic treatment is believed to repress the detrusor
overactivity associated with OAB by blocking the muscarinic
receptors in the detrusor muscle. However, several studies [19–21]
have shown that antimuscarinic treatment also significantly
improves sensory functions, as shown by increased time to first
sensation to void and reduced voiding frequency. On the basis of
these observations, we proposed that solifenacin treatment may
improve the frequency symptoms of subjects without urgency.
Table 1. Demographics and baseline characteristics.
Variables
Frequency without urgency
group (Group 1, n =115)
Frequency with urgency
group (Group 2, n=125) p-value
Age, years, mean (range) 57.46 (26–86) 56.60 (22–82) 0.60
Sex, n (%) 0.14
Men 26 (22.61) 19 (15.20)
Women 89 (77.39) 106 (84.80)
Symptom duration, months, mean (range) 56.46 (3–480) 65.93 (3–720) 0.42
Voiding diary/24 hour
Frequency, mean (range) 12.32 (8.33–22.67) 13.16 (8–32) 0.09
Nocturia, mean (range) 1.86 (0–10.33) 1.74 (0–6) 0.45
Bladder volume, ml, mean (range) 138.34 (32.22–292.31) 136.78 (42.5–315.56) 0.83
OABSS grade, n (%)
Mild 80 (69.57) 15 (12.00) ,0.0001
Moderate 32 (27.83) 89 (71.20)
Severe 3 (2.61) 21 (16.80)
Uroflowmetry parameters
Maximal flow rate, ml/s, mean (range) 19.24 (10.4–61.6) 21.53 (10.3–56.5) 0.12
Voided volume, ml, mean (range) 229.75 (122.5–871.5) 215.72 (122.7–831) 0.45
Post-voided residual, ml, mean (range) 25.18 (0–92) 23.35 (0–99) 0.65
doi:10.1371/journal.pone.0112063.t001
Table 2. Non-inferior analysis of solifenacin in patients with urinary frequency with or without urgency.
Variables Frequency without urgency group (Group 1) Frequency with urgency group (Group 2) p- value
Baseline 12.3260.31 13.1660.38 0.09
Week 12 9.8260.36 10.5260.42 0.21
Change from baseline 22.4960.35 22.6360.37 0.78
95% CI 23.17, 21.81 23.37, 21.90 -
95% CI for difference 23.37, 21.90
doi:10.1371/journal.pone.0112063.t002
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Overall, the 12-week solifenacin treatment was well tolerated in
the patients with frequency with and without urgency.
One limitation of this study was that we did not find that
solifenacin had a non-inferior effect on frequency without urgency
relative to its effect on frequency with urgency in terms of change
in daily micturition frequency (the primary endpoint of this study).
However, our study did show that solifenacin treatment signifi-
cantly decreased the daily micturition frequency in patients with
frequency regardless of urgency. Moreover, the difference between
the urgency and non-urgency groups in terms of micturition
frequency change did not achieve statistical significance. The
inability of this study to detect non-inferiority may reflect the wide
standard deviation (22.56) associated with the mean number of
micturitions per 24 hour that was reported by the study that was
used to establish the margin of clinical equivalence for the present
study [9]. The second limitation was that there was no placebo
Table 3. Patients’ perception of treatment benefit, satisfaction, and willing to have retreatment and Changes in Patients’
Perception of Bladder Condition scores.
Variables Frequency without urgency group (Group 1, n =115) Frequency with urgency group (Group 2, n=125) p-value
Treatment benefit, satisfaction, and willing to have retreatment
Benefit 69.9% 73.8% 0.55
Satisfaction 66.3% 75.7% 0.15
Retreatment 83.1% 88.8% 0.26
Change in Patients’ Perception of Bladder Condition scores
Deterioration 6.0% 6.5% 0.84
No change 16.9% 17.6% 0.72
1-point improvement 30.1% 24.1% 0.41
$2-point improvement 47.0% 51.9% 0.51
doi:10.1371/journal.pone.0112063.t003
Table 4. Treatment-emergent adverse events in both groups.
Variables Frequency without urgency group (Group 1, n =115) Frequency with urgency group (Group 2, n =125)
Subjects with AEs, n (%) 36 (25.5) 57 (39.3)
Dry mouth 13 (36.1) 32 (56.2)
Mild 11 25
Moderate 2 6
Severe - 1
Constipation 2 (5.6) 5 (8.8)
Mild 1 4
Moderate 1 1
Severe - -
Blurred vision 1 (2.8) 4 (7.0)
Mild 1 4
Dyspepsia 6 (16.6) 5 (8.8)
Mild 4 4
Moderate 2 1
Dizziness 1 (2.8) 1 (1.7)
Moderate 1 1
Voiding difficulty 7 (19.4) 8 (14.1)
Mild 6 6
Moderate 1 2
Headache 1 (2.8) -
Mild 1
Fatigue 2 (5.6) 1 (1.7)
Mild 2 1
Itching 3 (8.3) 1 (1.7)
Mild 3 1
doi:10.1371/journal.pone.0112063.t004
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group. The placebo response for OAB symptoms is a well-known
occurrence during drug trials. Although this was not a placebo-
controlled study, we tried to eliminate the effects of the placebo
response by recording the voiding diary during the screening
period. The placebo response during drug trials in OAB can be
partly attributable to the bladder training effect of completing a
voiding diary [22]. Through the process of recording and
reviewing the voiding diary, patients can become more aware of
voiding frequency and they may establish more appropriate
voiding intervals. At the initial screening visit, the lifestyle
modification (avoidance of bladder irritants such as caffeine),
bladder training, and voiding diary were explained, and during the
3 days before the next visit, patients recorded episodes in a 3-day
voiding diary. Patients were then assigned to one of two groups.
And, a total of 256 subjects enrolled could not reach 80% power to
detect non-inferiority because of unexpected subject dropout. We
assumed that, although we showed that solifenacin tended to be
effective for frequency regardless of urgency, we could not have
shown non-inferiority because of low power.
Conclusions
It was not possible to verify that the solifenacin efficacy for
frequency alone was non-inferior to its efficacy for OAB.
Nevertheless, solifenacin tended to be effective for frequency
regardless of urgency.
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